Frequency Analysis of Autoreactive T-helper 1 and 2 Cells in Bullous Pemphigoid and Pemphigus Vulgaris by Enzyme-linked Immunospot Assay
Overview
Affiliations
Background: Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are autoimmune bullous skin diseases mediated by autoantibodies against adhesion molecules of the skin. Previous studies have identified autoreactive T cells in patients with BP and PV, which may be critical in providing B-cell help for autoantibody production.
Objectives: To evaluate the frequency of autoreactive T-helper (Th) 1 and Th2 cells in patients with BP (n = 7) or PV (n = 1) and in healthy controls (n = 11).
Methods: In an enzyme-linked immunospot (ELISPOT) assay, microtitre plates were coated with antihuman interleukin (IL)-5 IgG or antihuman interferon (IFN)-gamma IgG prior to culturing human peripheral blood lymphocytes (PBL) with BP180 or desmoglein (Dsg) 3 proteins for 7 days. Cytokine-producing autoreactive T cells were visualized as spot-forming units.
Results: One BP patient with extensive blisters had 5.1 +/- 1.5 (mean +/- SD) BP180-reactive Th1 cells and 2.9 +/- 1.5 Th2 cells per 105 PBL. In contrast, PBL from six BP patients in remission or on immunosuppressive therapy did not form IFN-gamma- or IL-5-producing spots per </= 5 x 105 PBL. The patient with oral PV had 4.7 +/- 2.4 Th1 cells and 3.0 +/- 0.4 Th2 cells per 105 PBL and a vigorous PBL response to Dsg3. In addition, three of 10 controls had BP180-reactive Th1 (2.7-13.8 per 105 PBL) and Th2 (0.3-1.8 per 105 PBL) cells and one control had 9.0 +/- 0.7 Th1 cells and 1.1 +/- 0.8 Th2 cells per 105 PBL, with reactivity to Dsg3. ELISPOT reactivity correlated with 3H-thymidine incorporation in six of seven patients and controls with autoreactive T-cell responses.
Conclusions: The ELISPOT assay seems to be promising for the quantitative and qualitative analysis of autoreactive T-cell responses in BP and PV.
Study of cytokine-induced immunity in bullous pemphigoid: recent developments.
Huang R, Hu L, Jiang F Ann Med. 2023; 55(2):2280991.
PMID: 38109924 PMC: 10732206. DOI: 10.1080/07853890.2023.2280991.
Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris.
Polakova A, Kauter L, Ismagambetova A, Didona D, Solimani F, Ghoreschi K Front Immunol. 2022; 13:979277.
PMID: 36203615 PMC: 9531257. DOI: 10.3389/fimmu.2022.979277.
The emerging role of T cells in pemphigus vulgaris: a systematic review.
Araghi F, Dadkhahfar S, Robati R, Tabary M, Shahidi-Dadras M Clin Exp Med. 2022; 23(4):1045-1054.
PMID: 35925475 DOI: 10.1007/s10238-022-00855-8.
Autoimmune Pemphigus: Latest Advances and Emerging Therapies.
Lim Y, Bohelay G, Hanakawa S, Musette P, Janela B Front Mol Biosci. 2022; 8:808536.
PMID: 35187073 PMC: 8855930. DOI: 10.3389/fmolb.2021.808536.
Autoreactive T-Lymphocytes in Inflammatory Skin Diseases.
Boehncke W, Brembilla N Front Immunol. 2019; 10:1198.
PMID: 31191553 PMC: 6549194. DOI: 10.3389/fimmu.2019.01198.